|
1
|
Siegel RL, Wagle NS, Cercek A, Smith RA
and Jemal A: Colorectal cancer statistics, 2023. CA Cancer J Clin.
73:233–254. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wolf D, Salcher S and Pircher A: The
multivisceral landscape of colorectal cancer metastasis:
Implications for targeted therapies. J Clin Invest.
134:e1783312024. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Association NHCOTPROCSOOCM: National
Health Commission guidelines for diagnosis and treatment of
colorectal cancer 2023 in China (English version). Chin J Cancer
Res. 35:197–232. 2023.PubMed/NCBI
|
|
4
|
Bien J and Lin A: A review of the
diagnosis and treatment of metastatic colorectal cancer. Jama-J Am
Med Assoc. 325:2404–2405. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Miranda E, Bianchi P, Destro A, Morenghi
E, Malesci A, Santoro A, Laghi L and Roncalli M: Genetic and
epigenetic alterations in primary colorectal cancers and related
lymph node and liver metastases. Cancer. 119:266–276. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Clemens AW, Lin S, Jain S, Su YH and Song
W: Detection of colorectal cancer-associated genetic and epigenetic
alterations in urine of patients with CRC. Cancer Res. 75:abs.
1561. 2015.https://doi.org/10.1158/1538-7445.AM2015-1561
View Article : Google Scholar
|
|
7
|
Nosho K, Kawasaki T, Ohnishi M, Suemoto Y,
Kirkner GJ, Zepf D, Yan L, Longtine JA, Fuchs CS and Ogino S:
mutation in colorectal cancer: Relationship with genetic and
epigenetic alterations. Neoplasia. 10:534–541. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jiang XL, Liu BY, Nie Z, Duan L, Xiong Q,
Jin Z, Yang C and Chen Y: The role of m6A modification in the
biological functions and diseases. Signal Transduct Tar. 6:742021.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Roundtree IA, Luo GZ, Zhang Z, Wang X,
Zhou T, Cui Y, Sha J, Huang X, Guerrero L, Xie P, et al: YTHDC1
mediates nuclear export of N6 - methyladenosine
methylated mRNAs. Elife. 6:e313112017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhu ZM, Huo FC, Zhang J, Shan HJ and Pei
DS: Crosstalk between m6A modification and alternative splicing
during cancer progression. Clin Transl Med. 13:e14602023.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fang Z, Mei WT, Qu C, Lu J, Shang L, Cao F
and Li F: Role of m6A writers, erasers and readers in cancer. Exp
Hematol Oncol. 11:452022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang
L, Jia G, Yu M, Lu Z, Deng X, et al: A METTL3-METTL14 complex
mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem
Biol. 10:93–95. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ping XL, Sun BF, Wang L, Xiao W, Yang X,
Wang WJ, Adhikari S, Shi Y, Lv Y, Chen YS, et al: Mammalian WTAP is
a regulatory subunit of the RNA N6-methyladenosine
methyltransferase. Cell Res. 24:177–189. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yue Y, Liu J, Cui X, Cao J, Luo G, Zhang
Z, Cheng T, Gao M, Shu X, Ma H, et al: VIRMA mediates preferential
m6A mRNA methylation in 3′UTR and near stop codon and
associates with alternative polyadenylation. Cell Discov. 4:102018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Patil DP, Chen CK, Pickering BF, Chow A,
Jackson C, Guttman M and Jaffrey SR: m(6)A RNA methylation promotes
XIST-mediated transcriptional repression. Nature. 537:369–373.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zheng G, Dahl JA, Niu Y, Fedorcsak P,
Huang CM, Li CJ, Vågbø CB, Shi Y, Wang WL, Song SH, et al: ALKBH5
Is a Mammalian RNA Demethylase that Impacts RNA Metabolism and
Mouse Fertility. Mol Cell. 49:18–29. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang
Y, Yi C, Lindahl T, Pan T, Yang YG and He C: 6-Methyladenosine in
nuclear RNA is a major substrate of the obesity-associated FTO. Nat
Chem Biol. 7:885–887. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN,
Chen ZH, Zeng ZL, Wang F, Zheng J, et al: METTL3 facilitates tumor
progression via an mA-IGF2BP2-dependent mechanism in colorectal
carcinoma. Mol Cancer. 18:1122019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun Y, Gong W and Zhang S: METTL3 promotes
colorectal cancer progression through activating JAK1/STAT3
signaling pathway. Cell Death Dis. 14:7652023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xiang S, Liang XL, Yin S, Liu J and Xiang
Z: N6-methyladenosine methyltransferase METTL3 promotes colorectal
cancer cell proliferation through enhancing MYC expression. Am J
Transl Res. 12:1789–1806. 2020.PubMed/NCBI
|
|
21
|
Zhou D, Tang W, Xu Y, Xu Y, Xu B, Fu S,
Wang Y, Chen F, Chen Y, Han Y and Wang G: METTL3/YTHDF2 m6A axis
accelerates colorectal carcinogenesis through epigenetically
suppressing YPEL5. Mol Oncol. 15:2172–2184. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu W, Si Y, Xu J, Lin Y, Wang JZ, Cao M,
Sun S, Ding Q, Zhu L and Wei JF: Methyltransferase like 3 promotes
colorectal cancer proliferation by stabilizing CCNE1 mRNA in an
m6A-dependent manner. J Cell Mol Med. 24:3521–3533. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mondal S, Adhikari N, Banerjee S, Amin SA
and Jha T: Matrix metalloproteinase-9 (MMP-9) and its inhibitors in
cancer: A minireview. Eur J Med Chem. 194:1122602020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Marshall DC, Lyman SK, McCauley S,
Kovalenko M, Spangler R, Liu C, Lee M, O'Sullivan C, Barry-Hamilton
V, Ghermazien H, et al: Selective Allosteric Inhibition of MMP9 is
efficacious in preclinical models of ulcerative colitis and
colorectal cancer. PLoS One. 10:e01270632015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Choi SH, Lee HJ, Jin YB, Jang J, Kang GY,
Lee M, Kim CH, Kim J, Yoon SS, Lee YS and Lee YJ: MMP9 Processing
of HSPB1 Regulates Tumor Progression. PLoS One. 9:e855092014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee MA, Park JH, Rhyu SY, Oh ST, Kang WK
and Kim HN: Wnt3a expression is associated with MMP-9 expression in
primary tumor and metastatic site in recurrent or stage IV
colorectal cancer. BMC Cancer. 14:1252014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bauer L, Takacs A, Slotta-Huspenina J,
Langer R, Becker K, Novotny A, Ott K, Walch A, Hapfelmeier A and
Keller G: Clinical significance of NOTCH1 and NOTCH2 expression in
gastric carcinomas: An immunohistochemical study. Front Oncol.
5:942015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Boonsongserm P, Angsuwatcharakon P,
Puttipanyalears C, Aporntewan C, Kongruttanachok N, Aksornkitti V,
Kitkumthorn N and Mutirangura A: Tumor-induced DNA methylation in
the white blood cells of patients with colorectal cancer. Oncol
Lett. 18:3039–3048. 2019.PubMed/NCBI
|
|
30
|
Barbieri I and Kouzarides T: Role of RNA
modifications in cancer. Nat Rev Cancer. 20:303–322. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen Z, Zhao P, Li FY, Wang Y, Smith AI,
Webb GI, Akutsu T, Baggag A, Bensmail H and Song J: Comprehensive
review and assessment of computational methods for predicting RNA
post-transcriptional modification sites from RNA sequences. Brief
Bioinform. 21:1676–1696. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Roundtree IA, Evans ME, Pan T and He C:
Dynamic RNA Modifications in gene expression regulation. Cell.
169:1187–1200. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zeng C, Huang W, Li Y and Weng H: Roles of
METTL3 in cancer: Mechanisms and therapeutic targeting. J Hematol
Oncol. 13:1172020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen H, Pan Y, Zhou Q, Liang C, Wong CC,
Zhou Y, Huang D, Liu W, Zhai J, Gou H, et al: METTL3 Inhibits
Antitumor Immunity by Targeting m6A-BHLHE41-CXCL1/CXCR2
Axis to promote colorectal cancer. Gastroenterology. 163:891–907.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wei X, Huo Y, Pi J, Gao Y, Rao S, He M,
Wei Q, Song P, Chen Y, Lu D, et al: METTL3 preferentially enhances
non-mA translation of epigenetic factors and promotes
tumourigenesis. Nat Cell Biol. 24:1278–1290. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zaccara S, Ries RJ and Jaffrey SR:
Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell
Biol. 20:608–624. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Huang H, Weng H, Sun W, Qin X, Shi H, Wu
H, Zhao BS, Mesquita A, Liu C, Yuan CL, et al: Recognition of RNA
N6-methyladenosine by IGF2BP proteins enhances mRNA
stability and translation. Nat Cell Biol. 20:285–295. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mizuno R, Kawada K, Itatani Y, Ogawa R,
Kiyasu Y and Sakai Y: The role of tumor-associated neutrophils in
colorectal cancer. Int J Mol Sci. 20:5292019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Song Z, Yang L, Hu W, Yi J, Feng F and Zhu
L: Effects of histone H4 hyperacetylation on inhibiting MMP2 and
MMP9 in human amniotic epithelial cells and in premature rupture of
fetal membranes. Exp Ther Med. 21:5152021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pirooz HJ, Jafari N, Rastegari M,
Fathi-Roudsari M, Tasharrofi N, Shokri G, Tamadon M, Sazegar H and
Kouhkan F: Functional SNP in microRNA-491-5p binding site of MMP9
3-UTR affects cancer susceptibility. J Cell Biochem. 119:5126–5134.
2018. View Article : Google Scholar : PubMed/NCBI
|
